Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Information for Infusion Sites

COVID-19 Monoclonal Antibody Therapeutics​

Infusion sites have an important role to play in the rapid administration of COVID-19 monoclonal antibody therapeutics to patients following a COVID-19 diagnosis. These products have been shown to reduce the need for hospitalization for eligible patients with mild to moderate symptoms, but these treatments are most beneficial when they are given to patients early in symptom progression.

Bamlanivimabbamlanivimab/etesevimab, and casirivimab/imdevimab are monoclonal antibody therapeutics that have received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration. The EUA requires administration of treatment as soon as possible after a confirmed positive test result and within 10 days of symptom onset. Infusion sites must facilitate a fast turnaround time between COVID-19 diagnosis and treatment with monoclonal antibody therapeutics for the products to be effective.

Sites that meet specific infrastructure requirements and adhere to certain procedures and processes are eligible to provide the treatment. To learn about these considerations for planning, acquiring, administering, seeking reimbursement, and more as they relate to your infusion site, check out the resources below.



  • This page last reviewed: March 18, 2021